Want to see FR:IVA full AI Analyst Report?
IVA Stock Chart & Stats
€4.82
-€0.02(-0.70%)
At close: 4:00 PM EST
€4.82
-€0.02(-0.70%)
Day’s Range― - ―
52-Week Range€2.62 - €6.20
Previous CloseN/A
Volume1.84K
Average Volume (3M)416.07K
Market Cap
€773.67M
Enterprise Value€394.42M
Total Cash (Recent Filing)€230.87M
Total Debt (Recent Filing)€59.86M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Sep 25, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume620,713
30 Day Avg. Volume416,066
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-25.87
Price to Sales (P/S)164.59
P/FCF Ratio-7.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.78Price Target Upside82.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)€3.60M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Funding RunwayProceeds from a recent US public offering have created a sizeable cash position that extends the operating runway into early 2027, reducing near‑term financing risk and supporting continued pivotal trial operations.
Clinical Trial Enrollment And ReadoutFull enrollment of the Phase 3 NATIV3 trial with planned topline data presentation at a major hepatology conference increases the probability of a definitive clinical readout that could significantly influence valuation.
Trial Design And EndpointsA randomized dosing structure, biopsy‑confirmed endpoints read by a central panel, and a composite primary endpoint of disease resolution or fibrosis improvement strengthen the trial's ability to generate robust data for regulatory consideration.
Bears Say
Concomitant Medication ConfoundingUse of GLP‑1 agonists and other diabetes therapies by a subset of participants could obscure the investigational treatment's effect and complicate interpretation of efficacy despite stratification measures.
Inventiva News
IVA FAQ
What was Inventiva SA’s price range in the past 12 months?
Inventiva SA lowest stock price was €2.62 and its highest was €6.20 in the past 12 months.
What is Inventiva SA’s market cap?
Inventiva SA’s market cap is €773.67M.
When is Inventiva SA’s upcoming earnings report date?
Inventiva SA’s upcoming earnings report date is Sep 25, 2026 which is in 83 days.
How were Inventiva SA’s earnings last quarter?
Inventiva SA released its earnings results on Mar 30, 2026. The company reported -€0.926 earnings per share for the quarter, missing the consensus estimate of -€0.237 by -€0.689.
Is Inventiva SA overvalued?
According to Wall Street analysts Inventiva SA’s price is currently Undervalued.
Does Inventiva SA pay dividends?
Inventiva SA does not currently pay dividends.
What is Inventiva SA’s EPS estimate?
Inventiva SA’s EPS estimate is -0.32.
How many shares outstanding does Inventiva SA have?
Inventiva SA has 236,280,200 shares outstanding.
What happened to Inventiva SA’s price movement after its last earnings report?
Inventiva SA reported an EPS of -€0.926 in its last earnings report, missing expectations of -€0.237. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Inventiva SA?
Currently, no hedge funds are holding shares in FR:IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inventiva SA
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
IVA Stock 12 Month Forecast
Average Price Target
€8.78
▲(82.10% Upside)
Technical Analysis
Options Prices
Currently, No data available
---